Cargando…

Clinical and prognostic (18)F-FDG PET/CT role in recurrent vulvar cancer: a multicentric experience

PURPOSE: The aim of this retrospective multicentric study was to investigate the diagnostic performance, the prognostic value and the impact of (18)F-FDG PET/CT on treatment decision-making in patients with suspected recurrent vulvar cancer (VC). MATERIALS AND METHODS: Sixty-three patients affected...

Descripción completa

Detalles Bibliográficos
Autores principales: Albano, Domenico, Bonacina, Mattia, Savelli, Giordano, Ferro, Paola, Busnardo, Elena, Gianolli, Luigi, Camoni, Luca, Giubbini, Raffaele, Bertagna, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732915/
https://www.ncbi.nlm.nih.gov/pubmed/34272721
http://dx.doi.org/10.1007/s11604-021-01173-x
_version_ 1784627703378345984
author Albano, Domenico
Bonacina, Mattia
Savelli, Giordano
Ferro, Paola
Busnardo, Elena
Gianolli, Luigi
Camoni, Luca
Giubbini, Raffaele
Bertagna, Francesco
author_facet Albano, Domenico
Bonacina, Mattia
Savelli, Giordano
Ferro, Paola
Busnardo, Elena
Gianolli, Luigi
Camoni, Luca
Giubbini, Raffaele
Bertagna, Francesco
author_sort Albano, Domenico
collection PubMed
description PURPOSE: The aim of this retrospective multicentric study was to investigate the diagnostic performance, the prognostic value and the impact of (18)F-FDG PET/CT on treatment decision-making in patients with suspected recurrent vulvar cancer (VC). MATERIALS AND METHODS: Sixty-three patients affected by VC performed (18)F-FDG-PET/CT for restaging purposes in case of suspected clinical and/or radiological recurrence. Histopatology results if available and/or clinical-imaging follow-up for at least 12 months were considered as reference standard. The diagnostic accuracy and the clinical impact of (18)F-FDG PET/CT were investigated. Progression free survival (PFS) and overall survival (OS) were calculated using Kaplan–Meier curves. RESULTS: Fifty-two (82.5%) PET/CT showed the presence of recurrence, while the remaining 11 (17.5%) were negative. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PET/CT were 100% (95%CI 93–100%), 92% (95%CI 62–100%), 98% (95%CI 89–99%), 100% and 98% (95%CI 92–100%). A relevant impact of (18)F-FDG PET/CT imaging was registered in 28 cases: in 12 cases moving from local therapy to chemotherapy due to the recognition of disseminate localizations; in 10 showing the site of recurrence in presence of negative conventional imaging, and in 6 cases confirming to be true negative and avoiding unnecessary therapies. Beside advanced age and HPV status, a positive restaging (18)F-FDG PET/CT scan was significantly correlated with shorter PFS and OS compared to negative scan (p < 0.001). CONCLUSIONS: (18)F-FDG PET/CT demonstrated to be an accurate tool in the assessing of recurrent VC with high sensitivity and specificity and with a significant impact on clinical decision-making. Restaging (18)F-FDG PET/CT findings were associated with survival.
format Online
Article
Text
id pubmed-8732915
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-87329152022-01-18 Clinical and prognostic (18)F-FDG PET/CT role in recurrent vulvar cancer: a multicentric experience Albano, Domenico Bonacina, Mattia Savelli, Giordano Ferro, Paola Busnardo, Elena Gianolli, Luigi Camoni, Luca Giubbini, Raffaele Bertagna, Francesco Jpn J Radiol Original Article PURPOSE: The aim of this retrospective multicentric study was to investigate the diagnostic performance, the prognostic value and the impact of (18)F-FDG PET/CT on treatment decision-making in patients with suspected recurrent vulvar cancer (VC). MATERIALS AND METHODS: Sixty-three patients affected by VC performed (18)F-FDG-PET/CT for restaging purposes in case of suspected clinical and/or radiological recurrence. Histopatology results if available and/or clinical-imaging follow-up for at least 12 months were considered as reference standard. The diagnostic accuracy and the clinical impact of (18)F-FDG PET/CT were investigated. Progression free survival (PFS) and overall survival (OS) were calculated using Kaplan–Meier curves. RESULTS: Fifty-two (82.5%) PET/CT showed the presence of recurrence, while the remaining 11 (17.5%) were negative. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PET/CT were 100% (95%CI 93–100%), 92% (95%CI 62–100%), 98% (95%CI 89–99%), 100% and 98% (95%CI 92–100%). A relevant impact of (18)F-FDG PET/CT imaging was registered in 28 cases: in 12 cases moving from local therapy to chemotherapy due to the recognition of disseminate localizations; in 10 showing the site of recurrence in presence of negative conventional imaging, and in 6 cases confirming to be true negative and avoiding unnecessary therapies. Beside advanced age and HPV status, a positive restaging (18)F-FDG PET/CT scan was significantly correlated with shorter PFS and OS compared to negative scan (p < 0.001). CONCLUSIONS: (18)F-FDG PET/CT demonstrated to be an accurate tool in the assessing of recurrent VC with high sensitivity and specificity and with a significant impact on clinical decision-making. Restaging (18)F-FDG PET/CT findings were associated with survival. Springer Singapore 2021-07-17 2022 /pmc/articles/PMC8732915/ /pubmed/34272721 http://dx.doi.org/10.1007/s11604-021-01173-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Albano, Domenico
Bonacina, Mattia
Savelli, Giordano
Ferro, Paola
Busnardo, Elena
Gianolli, Luigi
Camoni, Luca
Giubbini, Raffaele
Bertagna, Francesco
Clinical and prognostic (18)F-FDG PET/CT role in recurrent vulvar cancer: a multicentric experience
title Clinical and prognostic (18)F-FDG PET/CT role in recurrent vulvar cancer: a multicentric experience
title_full Clinical and prognostic (18)F-FDG PET/CT role in recurrent vulvar cancer: a multicentric experience
title_fullStr Clinical and prognostic (18)F-FDG PET/CT role in recurrent vulvar cancer: a multicentric experience
title_full_unstemmed Clinical and prognostic (18)F-FDG PET/CT role in recurrent vulvar cancer: a multicentric experience
title_short Clinical and prognostic (18)F-FDG PET/CT role in recurrent vulvar cancer: a multicentric experience
title_sort clinical and prognostic (18)f-fdg pet/ct role in recurrent vulvar cancer: a multicentric experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732915/
https://www.ncbi.nlm.nih.gov/pubmed/34272721
http://dx.doi.org/10.1007/s11604-021-01173-x
work_keys_str_mv AT albanodomenico clinicalandprognostic18ffdgpetctroleinrecurrentvulvarcanceramulticentricexperience
AT bonacinamattia clinicalandprognostic18ffdgpetctroleinrecurrentvulvarcanceramulticentricexperience
AT savelligiordano clinicalandprognostic18ffdgpetctroleinrecurrentvulvarcanceramulticentricexperience
AT ferropaola clinicalandprognostic18ffdgpetctroleinrecurrentvulvarcanceramulticentricexperience
AT busnardoelena clinicalandprognostic18ffdgpetctroleinrecurrentvulvarcanceramulticentricexperience
AT gianolliluigi clinicalandprognostic18ffdgpetctroleinrecurrentvulvarcanceramulticentricexperience
AT camoniluca clinicalandprognostic18ffdgpetctroleinrecurrentvulvarcanceramulticentricexperience
AT giubbiniraffaele clinicalandprognostic18ffdgpetctroleinrecurrentvulvarcanceramulticentricexperience
AT bertagnafrancesco clinicalandprognostic18ffdgpetctroleinrecurrentvulvarcanceramulticentricexperience